Sign In
Buy PRPH
$0.0900
+0.0120 (+15.38%)
At Close: Jun 23, 2026
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – What’s Next?
03:54am, Friday, 24'th Apr 2026
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.24 and traded as low as $0.
ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – What’s Next?
03:20am, Thursday, 16'th Apr 2026
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.42 and traded as lo
$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potent
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – Time to Sell?
02:40am, Friday, 27'th Mar 2026
Shares of ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.86 and traded as low as
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
08:00am, Tuesday, 17'th Mar 2026
Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
07:00am, Tuesday, 03'rd Feb 2026
Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase"
UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided an ope
ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
03:50am, Wednesday, 14'th Jan 2026
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.12 and traded as low as $0.
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?
04:51am, Tuesday, 06'th Jan 2026
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.26 and traded as low as $0.16
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
05:00am, Monday, 05'th Jan 2026
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's un
Head to Head Contrast: Hikma Pharmaceuticals (OTCMKTS:HKMPF) vs. ProPhase Labs (NASDAQ:PRPH)
05:20am, Sunday, 28'th Dec 2025
ProPhase Labs (NASDAQ: PRPH - Get Free Report) and Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
09:48am, Friday, 19'th Dec 2025
DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driv
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
07:00am, Friday, 19'th Dec 2025
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.
ProPhase Labs (NASDAQ:PRPH) versus Grifols (NASDAQ:GRFS) Head to Head Survey
02:54am, Tuesday, 02'nd Dec 2025
Grifols (NASDAQ: GRFS - Get Free Report) and ProPhase Labs (NASDAQ: PRPH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on th
ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript
